ERIC-GTN: Investigation Into the Role of GTN & RIPC in Cardiac Surgery

Sponsor
University College, London (Other)
Overall Status
Completed
CT.gov ID
NCT01864252
Collaborator
University College London Hospitals (Other)
192
1
4
61
3.1

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether Glyceryl Trinitrate (GTN) reduces injury to the heart during heart-lung bypass surgery in combination with the newer technique of remote ischaemic preconditioning (RIPC).

Condition or Disease Intervention/Treatment Phase
  • Other: Remote ischaemic preconditioning
  • Drug: IV Normal saline
  • Drug: IV Glyceryl trinitrate 2-5ml/h
Phase 3

Detailed Description

Ischaemic heart disease is a leading cause of mortality in the western world. A number of patients undergo coronary artery bypass graft (CABG) surgery as treatment for ischaemic heart disease. With the rise of interventional procedures, patients who are coming to have CABG surgery are higher risk1. Remote ischaemic preconditioning (RIPC) has been shown to reduce perioperative myocardial injury (PMI) in patients having CABG even when cold blood cardioplegia or intermittent cross clamp fibrillation is used as cardioprotective measures. These patients have a general anaesthetic with multiple infusions including Glyceryl Trinitrate (GTN). The use of GTN in these patients is based on theoretical assumptions of coronary vasodilation pre operatively along with maintaining graft potency postoperatively. We intend to investigate the effect of GTN in patients undergoing cardiac surgery being subjected to RIPC in its role as a Nitric Oxide (NO) donor. Exogenous NO has been shown to be cardioprotective in animal models.

Study Design

Study Type:
Interventional
Actual Enrollment :
192 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
The Effect of Remote Ischaemic Preconditioning and Glyceryl Trinitrate on Peri-operative Myocardial Injury in Cardiac Bypass Surgery Patients (ERIC-GTN Study)
Actual Study Start Date :
Jan 1, 2014
Actual Primary Completion Date :
Oct 1, 2018
Actual Study Completion Date :
Feb 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Sham Comparator: Group 1 Control (65 patients)

Sham Remote ischaemic preconditioning with IV normal saline 2-5ml/hour.

Drug: IV Normal saline
Normal saline IV started prior to knife to skin at a rate of 2-5 mls/h and stopped just after weaning off bypass.

Active Comparator: Group 2 (65 patients)

Patients administered a Remote Ischaemic preconditioning protocol (three-5 min cycles of simultaneous inflation to cuffs placed on upper arm and thigh) prior to surgery and IV normal saline 2-5 mL/h during surgery.

Other: Remote ischaemic preconditioning
3 cycles of 5 minutes to arm and legs

Drug: IV Normal saline
Normal saline IV started prior to knife to skin at a rate of 2-5 mls/h and stopped just after weaning off bypass.

Experimental: Group 3 GTN (65 patients):

Patients administered sham simulated Remote Ischaemic Preconditioning protocol prior to surgery and IV Glyceryl Trinitrate 2-5ml/h during surgery.

Drug: IV Glyceryl trinitrate 2-5ml/h
IV GTN given during surgery started prior to knife to skin and stopped after weaning off cardiopulmonary bypass.

Experimental: • Group 4 RIPC+GTN (65 patients):

Patients administered Remote Ischaemic Preconditioning protocol and IV Glyceryl Trinitrate during surgery

Other: Remote ischaemic preconditioning
3 cycles of 5 minutes to arm and legs

Drug: IV Glyceryl trinitrate 2-5ml/h
IV GTN given during surgery started prior to knife to skin and stopped after weaning off cardiopulmonary bypass.

Outcome Measures

Primary Outcome Measures

  1. Troponin T area under the curve [72 hours]

    Troponin T area under the curve will be calculated using blood samples collected at 0,6,12,24,48 and 72 hours plotting it against time to calculated AUC.

Secondary Outcome Measures

  1. Inotrope/Vasopressor requirements peri-operatively [Post-operative day 1,2,3 and 4]

    The inotrope score will be calculated as follows: Dosages (in μg/kg/min) of [Dopamine + Dobutamine] + [(Adrenaline + Noradrenaline + Isoproterenol + Isoproterenol) x 100] + [(Enoximone + Milrinone) x 15]

  2. Ventilator dependence post operatively [Post-operative day 1,2,3 and 4]

    The duration of endotracheal intubation will be noted in hours. Re-intubation rates will be calculated by noting down the number of patients requiring re-intubation and comparing this amongst the 4 groups.

  3. Incidence of Acute Kidney Injury assessed using biomarkers [Post-operative day 1,2,3 and 4]

    Serum creatinine levels will be noted in the first 3 days postoperatively. If a patient requires renal replacement therapy, this will be recorded and comparisons made amongst the groups. Hourly urine output and daily urine volumes for the duration of ITU stay will be recorded.

  4. Length of ITU stay [Average 4 days]

    A record of stay in days will be noted

  5. Length of hospital stay [Average 14 days]

    Duration of hospital stay will be recorded in days

  6. Incidence of post-operative atrial fibrillation [Post-operative day 1,2,3 and 4]

    Atrial fibrillation will be diagnosed using ECG. A record of the number of patients developing AF post operatively, the intervention used to treat it and whether or not the patient reverted to sinus rhythm prior to ITU discharge will be documented

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age > 18 years all patients admitted for on- pump CABG and/or valve surgery

  • Able to give consent

Exclusion Criteria:
  • Allergies to excipients of IMP and placebo

  • Chronic Renal failure (eGFR<30 ml/min/kg)

  • Severe liver disease

  • Peripheral arterial disease

  • Pregnant or lactating women

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Heart Hospital, UCL Hospitals NHS Trust London United Kingdom NW1 2PG

Sponsors and Collaborators

  • University College, London
  • University College London Hospitals

Investigators

  • Principal Investigator: Derek Yellon, PhD DSc FRCP, The Hatter Cardiovascular Institute

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University College, London
ClinicalTrials.gov Identifier:
NCT01864252
Other Study ID Numbers:
  • 120541
First Posted:
May 29, 2013
Last Update Posted:
Sep 25, 2019
Last Verified:
Sep 1, 2019

Study Results

No Results Posted as of Sep 25, 2019